{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-193906","form_type":"8-K","ticker":null,"cik":"0001785173","company_name":"89bio, Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.517091+00:00","generated_at":"2026-05-31T13:11:49.181331+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"89bio Q2 net loss $48M; appoints ex-CymaBay CSO Charles McWherter to board; Phase 3 MASH trials enrolling","bullets":["Net loss $48.0M for Q2 2024 vs $38.4M YoY; R&D expenses rose to $44.9M.","Cash, equivalents and marketable securities $531.4M as of June 30, 2024.","Phase 3 ENLIGHTEN-Fibrosis (F2-F3 MASH) and ENLIGHTEN-Cirrhosis (F4) enrolling patients.","Phase 3 ENTRUST (SHTG) topline data expected in 2025; enrollment ongoing.","Charles McWherter, Ph.D., former CSO/President R&D of CymaBay (acquired by Gilead), appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-193906","json":"https://secwatch.observer/filing/0001193125-24-193906.json","markdown":"https://secwatch.observer/filing/0001193125-24-193906.md","text":"https://secwatch.observer/filing/0001193125-24-193906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/0001193125-24-193906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/d879198d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:11:49.181331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4647051ef","claim":"Charles McWherter was appointed as member of the Board at 89bio, Inc..","evidence_excerpt":"On July 30, 2024, the board of directors (the “Board”) of the Company appointed Charles McWherter, Ph.D. as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/0001193125-24-193906-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}